OKYO - Latest News
OKYO Pharma Limited (OKYO), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $55.2M. Beta to the broader market is 0.04.
The article list below shows the most recent OKYO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent OKYO Headlines
OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug
proactiveinvestors.com - Oct 6, 2026
OKYO Pharma Ltd (NASDAQ:OKYO) enrolled the first patients in its Phase 3 trial of urcosimod for neuropathic corneal pain, a chronic and often severe e
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
globenewswire.com - Oct 6, 2026
LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing inve
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
globenewswire.com - Sep 29, 2026
LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing inv
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
globenewswire.com - Sep 9, 2026
LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing inv
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
globenewswire.com - Sep 8, 2026
LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing inv
How News Affects OKYO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track OKYO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked OKYO news questions
- What is the latest OKYO news headline?
- The most recent OKYO headline (Oct 6, 2026) is "OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the OKYO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What OKYO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual OKYO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.